INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
10/02/2026
Voltar para busca
Dado oficial do USPTO
IMMUNOSIGN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
IMMUNOSIGN
ST13
US500000079214190Classe
5, 9, 10, 44
Pedido
79214190
Registro
5572566
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
11/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10, 44
Data de depósito
20/01/2017
Data de registro
02/10/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/12/2024
Última transação
11/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
Marseille, FR
Examinador
CROWLEY, SEAN MICHAEL
Localização atual
Historical data usage
Titulares e representantes
Titulares
Veracyte
HalioDx
HalioDx
Representantes
Douglas R. Wolf Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products being chemical or biological preparations for medical and pharmaceutical use for use in vitro testingfor use in the clinical diagnosticprognosismonitoringprediction of response to treatments and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition; biological reagents for medical use for providing information on diagnostic or identification of biological systems; biological reagents for pharmaceutical use for providing information on diagnostics or identification of biological systems
Classe 9
Software for use in the clinical diagnosisprognosismonitoringprediction of response to treatments and on-going evaluationanalysis and study of a cancertumor or equivalent medical conditionin the field of biology; application software in the nature of a mobile application for use in the clinical diagnosisprognosismonitoringprediction of response to treatments and on-going evaluationanalysis and study of a cancertumor or equivalent medical condition in the field of biology
Classe 10
medical apparatus and instruments for providing information on diagnostics or identification of biological systemsgene expression analysis and markers detection devicesmedical testing devices and diagnostic apparatus for detectinganalyzing or assessing a cancertumor or equivalent medical condition; medical instruments for cell detection in the context of a cancertumor or equivalent medical condition
Classe 44
Medical analysis services; medical assistance; health services; medical therapeutic services; medical diagnosticsdiagnostics in the field of medicine; genetic analysis services for medical purposesanalysis of a medical disordertumorcancer or equivalent medical condition
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
INPC
INVALIDATION PROCESSED
10/02/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
26/08/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/08/2025
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
26/12/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
26/12/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/12/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
22/05/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/10/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/02/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/02/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/01/2019
FIMP
FINAL DISPOSITION PROCESSED
14/01/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/01/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
02/10/2018
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
17/07/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/07/2018
PUBO
PUBLISHED FOR OPPOSITION
17/07/2018
GPNX
NOTIFICATION PROCESSED BY IB
14/07/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/06/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/06/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
27/06/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/06/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2018
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
08/06/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/06/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/04/2018
GNRT
NON-FINAL ACTION E-MAILED
05/04/2018
CNRT
NON-FINAL ACTION WRITTEN
05/04/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/02/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/02/2018
ALIE
ASSIGNED TO LIE
23/02/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/02/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/01/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/01/2018
RFNT
REFUSAL PROCESSED BY IB
15/09/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/08/2017
RFRR
REFUSAL PROCESSED BY MPU
25/08/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/08/2017
CNRT
NON-FINAL ACTION WRITTEN
23/08/2017
MAFR
APPLICATION FILING RECEIPT MAILED
22/08/2017
DOCK
ASSIGNED TO EXAMINER
16/08/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/08/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/08/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IMMUNOSIGN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.